Titre
Outcomes of stage III NSCLC (single N2 vs bulky N2/N3) managed by surgery or definitive radiation therapy in the era of immunotherapy
Type
mémoire de master/maîtrise/licence
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
ZERMATTEN, L.
Auteure/Auteur
Directrices/directeurs
PERENTES, J.
Directeur⸱rice
ABDELNOUR-BERCHTOLD, E.
Codirecteur⸱rice
Liens vers les personnes
Liens vers les unités
Faculté
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Accepté
Date de publication
2024
Nombre de pages
22
Langue
anglais
Résumé
Introduction
The introduction of immunotherapy (IO) in the management of locally advanced non-small cell lung cancers (NSCLCs) has significantly improved patient outcomes. In 2017, our center introduced compassionate IO for stage III NSCLC as follows: induction chemo-IO followed by surgery for potentially resectable and chemo-radiation therapy followed by IO for non- operable NSCLCs. Here, we report the outcomes of 68 stage III NSCLCs (45 single N2 and 23
bulky N2 or N3) managed by multimodal therapy including IO and surgery or radiation therapy.
Methods
This study is retrospective and was conducted at the Lausanne University Hospital (CHUV). We reviewed all stage III NSCLC patients treated in our institution between 2017 and 2023 with chemo-IO and surgery or radiation therapy. We recorded and analyzed, for each patient, clinico-pathological characteristics, perioperative complications and long-term outcomes. Descriptive statistics were performed using Stata software®.
Results
A total of 68 patients were included in the study: 32 underwent surgery and 36 underwent radiation therapy. Tumor oncological stages were less advanced in the surgical group (81% stage IIIA-single N2 and 19% stage IIIB-bulky N2/N3) than in the radiation therapy group (53% stage IIIA-single N2 and 47% stage IIIB-bulky N2/N3 disease). Also, compared to radiation therapy group, patients from the surgery group were younger (63 years [56-69] vs 75 years [63-73]) and had better pulmonary functions (FEV1 85.47 ± 16.88, DLCO 74.88 ± 17.15 vs FEV1
61.44 ± 27.42, and DLCO 45.23 ± 21.46). Of the 33 patients induced by chemo-IO, 32 underwent surgery while one progressed and underwent radiation therapy. Surgical procedures included 31 lobectomies or bilobectomies (97%) and 1 pneumonectomy (3%). Complete resection (R0) was achieved in 30 patients (94%), while two patients (6%) had an R1 resection due to lymph node effraction. Treatment-related complications were comparable (14% of cardiac and 36% of pulmonary vs 19% cardiac and 41% pulmonary in the radiation and surgery groups respectively). There was no 30-day mortality reported in either group. A complete pathological response (CPR) was observed in 7 surgical patients, including 6 of 26 with single N2 disease and 1 of 6 with bulky N2/N3 disease. Mean patient survival was of 100% in the CPR patients and tended to be higher in the surgery group compared to the radiation therapy group.
Conclusion
The inclusion of IO has significantly improved tumor response rates irrespective of the local treatment modality. Chemo-IO induction protocols can be considered in fit patients for more advanced stage III disease with good results. Nevertheless, careful patient selection through multidisciplinary tumor boards remains essential as the radiation alternative is a good option.
Further research is required to validate these findings.
The introduction of immunotherapy (IO) in the management of locally advanced non-small cell lung cancers (NSCLCs) has significantly improved patient outcomes. In 2017, our center introduced compassionate IO for stage III NSCLC as follows: induction chemo-IO followed by surgery for potentially resectable and chemo-radiation therapy followed by IO for non- operable NSCLCs. Here, we report the outcomes of 68 stage III NSCLCs (45 single N2 and 23
bulky N2 or N3) managed by multimodal therapy including IO and surgery or radiation therapy.
Methods
This study is retrospective and was conducted at the Lausanne University Hospital (CHUV). We reviewed all stage III NSCLC patients treated in our institution between 2017 and 2023 with chemo-IO and surgery or radiation therapy. We recorded and analyzed, for each patient, clinico-pathological characteristics, perioperative complications and long-term outcomes. Descriptive statistics were performed using Stata software®.
Results
A total of 68 patients were included in the study: 32 underwent surgery and 36 underwent radiation therapy. Tumor oncological stages were less advanced in the surgical group (81% stage IIIA-single N2 and 19% stage IIIB-bulky N2/N3) than in the radiation therapy group (53% stage IIIA-single N2 and 47% stage IIIB-bulky N2/N3 disease). Also, compared to radiation therapy group, patients from the surgery group were younger (63 years [56-69] vs 75 years [63-73]) and had better pulmonary functions (FEV1 85.47 ± 16.88, DLCO 74.88 ± 17.15 vs FEV1
61.44 ± 27.42, and DLCO 45.23 ± 21.46). Of the 33 patients induced by chemo-IO, 32 underwent surgery while one progressed and underwent radiation therapy. Surgical procedures included 31 lobectomies or bilobectomies (97%) and 1 pneumonectomy (3%). Complete resection (R0) was achieved in 30 patients (94%), while two patients (6%) had an R1 resection due to lymph node effraction. Treatment-related complications were comparable (14% of cardiac and 36% of pulmonary vs 19% cardiac and 41% pulmonary in the radiation and surgery groups respectively). There was no 30-day mortality reported in either group. A complete pathological response (CPR) was observed in 7 surgical patients, including 6 of 26 with single N2 disease and 1 of 6 with bulky N2/N3 disease. Mean patient survival was of 100% in the CPR patients and tended to be higher in the surgery group compared to the radiation therapy group.
Conclusion
The inclusion of IO has significantly improved tumor response rates irrespective of the local treatment modality. Chemo-IO induction protocols can be considered in fit patients for more advanced stage III disease with good results. Nevertheless, careful patient selection through multidisciplinary tumor boards remains essential as the radiation alternative is a good option.
Further research is required to validate these findings.
PID Serval
serval:BIB_44CE5803836C
Date de création
2024-09-02T08:14:00.447Z
Date de création dans IRIS
2025-05-20T18:27:24Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
Mémoire no 10968 Mme Zermatten Laetitia.pdf
Version du manuscrit
imprimatur
Taille
504.44 KB
Format
Adobe PDF
PID Serval
serval:BIB_44CE5803836C.P001
Somme de contrôle
(MD5):f4d38522dfde3e52a5ff80101d5ebcdc